CDK4 and neoplasm: Moreover, the combination of palbociclib and binimetinib (targeting CDK4/6 and MEK, respectively) was shown to induce tumor cell senescence and matrix remodeling leading to enhanced drug delivery and T-cell infiltration, supporting further study of the combination.